A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
AstraZeneca
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
M.D. Anderson Cancer Center
Novartis
Northwestern University